{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Fenor de la Maza MD"],"funding":["Cancer Research UK","National Institute for Health Research (NIHR)","Wellcome Trust"],"pagination":["659-667"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7617991"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["5(6)"],"pubmed_abstract":["<h4>Background</h4>Metastatic castration-resistant prostate cancer (mCRPC) is a heterogeneous disease in which molecular stratification is needed to improve clinical outcomes. The identification of predictive biomarkers can have a major impact on the care of these patients, but the availability of metastatic tissue samples for research in this setting is limited.<h4>Objective</h4>To study the prevalence of immune biomarkers of potential clinical utility to immunotherapy in mCRPC and to determine their association with overall survival (OS).<h4>Design, setting, and participants</h4>From 100 patients, mCRPC biopsies were assayed by whole exome sequencing, targeted next-generation sequencing, RNA sequencing, tumor mutational burden, T-cell-inflamed gene expression profile (TcellinfGEP) score "],"journal":["European urology oncology"],"pubmed_title":["Immune Biomarkers in Metastatic Castration-resistant Prostate Cancer."],"pmcid":["PMC7617991"],"funding_grant_id":["219594/Z/19/Z","NF-SI-0617-10099"],"pubmed_authors":["Sharp A","Chandran K","de Bono JS","Liu XQ","Carreira S","Bertan C","Riisnaes R","Westaby D","Rodrigues DN","Rekowski J","Schloss C","Seed G","Cross E","Gurel B","Cristescu R","Yuan W","Figueiredo I","Ferreira A","Shui IM","Fenor de la Maza MD","Miranda S","Rescigno P","Tunariu N","Yap C","Gil V","Crespo M"],"additional_accession":[]},"is_claimable":false,"name":"Immune Biomarkers in Metastatic Castration-resistant Prostate Cancer.","description":"<h4>Background</h4>Metastatic castration-resistant prostate cancer (mCRPC) is a heterogeneous disease in which molecular stratification is needed to improve clinical outcomes. The identification of predictive biomarkers can have a major impact on the care of these patients, but the availability of metastatic tissue samples for research in this setting is limited.<h4>Objective</h4>To study the prevalence of immune biomarkers of potential clinical utility to immunotherapy in mCRPC and to determine their association with overall survival (OS).<h4>Design, setting, and participants</h4>From 100 patients, mCRPC biopsies were assayed by whole exome sequencing, targeted next-generation sequencing, RNA sequencing, tumor mutational burden, T-cell-inflamed gene expression profile (TcellinfGEP) score ","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Dec","modification":"2026-04-15T19:25:25.495Z","creation":"2026-04-07T14:01:21.665Z"},"accession":"S-EPMC7617991","cross_references":{"pubmed":["35491356"],"doi":["10.1016/j.euo.2022.04.004"]}}